Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

liver solid financial results and to advance our late-stage pipeline, with four regulatory filings completed this year alone," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We are successfully executing our strategy which will enable us to return to growth after 2014 by bringing to the market new medicines that make a real difference for patients."

"We remain committed to our innovation strategy and believe it will drive growth and expand margins post-2014," added Derica Rice, Lilly executive vice president, global services and chief financial officer. "We will also return substantial cash to shareholders by maintaining our dividend at least at its current level and by repurchasing shares under our recently-authorized $5 billion program."

Key Events Over the Last Three Months

  • Dulaglutide was submitted for regulatory review in both the U.S. and Europe as a potential treatment for type 2 diabetes.
  • The U.S. rolling submission was completed for ramucirumab as a single-agent treatment for patients with advanced gastric cancer who have had disease progression after initial chemotherapy. A submission for ramucirumab for the same indication was also made in Europe.
  • Top-line results were announced from two global Phase III studies of ramucirumab. In the first study, ramucirumab, in combination with paclitaxel in patients with advanced gastric cancer, met its primary endpoint of improved overall survival and a secondary endpoint of improved progression-free survival. A second study of ramucirumab in women with locally recurrent or metastatic breast cancer did not meet its primary endpoint of progression-free survival.
  • A recently completed Phase III study for necitumumab met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
    2. Lilly Declares Fourth-Quarter 2013 Dividend
    3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
    4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
    5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
    6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
    7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
    8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
    9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
    10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
    11. Lilly Reports Second-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... 23, 2014 The Board of Directors of ... provider of clinical trial imaging solutions, announced today that ... president and chief executive officer, effective immediately.  Mr. Converse ... and has held the positions of interim president and ... Dr. Charles E. Phelps , Ph.D., chairman of ...
    (Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
    (Date:7/23/2014)... July 23, 2014 On Tuesday, July ... filed suit in the 116 th Judicial ... , against RegenLab USA, LLC ("Defendant") ... Business Relationships through false and misleading actions, ... Business Disparagement through libel, disparagement, defamation, misrepresentation, ...
    Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
    (Date:7/23/2014)... Home Care Assistance Calgary , North America’s ... to announce the next installment in its renowned Healthy ... of health and wellness-related fields. The upcoming webinar will ... Kriseman, and will cover the most common causes of ... more self-aware. In particular, Nancy will discuss mindfulness and ...
    (Date:7/23/2014)... (HealthDay News) -- Regularly checking the pulse of a ... "Screening pulse is the method of choice for ... who have never had a stroke. Our study shows ... way to identify people who might need more thorough ... Dr. Bernd Kallmunzer, of Erlangen University in Germany. ...
    (Date:7/23/2014)... Institute of Biomedical Imaging and Bioengineering will host its ... 30, 2014 on the NIH campus. There will be ... wide breadth of NIBIB-funded research. , WHO: ... Microbial Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, ... for Nerve Imaging during Surgery, ...
    (Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
    (Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
    Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
    ... The following is a,statement from the Trust for America,s ... major health crisis because the United States does not,have ... Americans are uninsured;, Tens of millions of Americans ... $2 trillion a year on medical care, more than,any ...
    ... have done it again!, SAN DIEGO, Dec. 14 ... Young -- The Owner,s Manual for,Extending Your Warranty, lived up ... Diet, both New York Times #1 best-sellers. Within days,of its ... and,Barnes & Noble.com. Within just a few weeks, it became ...
    ... Dec. 14 Following is a statement,by Linda ... Products,Association (CHPA), regarding the recommendations of the U.S. ... phenylephrine:, "Phenylephrine 10 mg is safe when ... effective for nasal decongestion in multiple clinical trials.,Today, ...
    ... more than 8 years of follow-up, older women taking ... Dec. 14 (HealthDay News) -- The aromatase inhibitor drug ... it comes to preventing recurrences of hormone-receptor-positive breast cancers ... was stopped, women taking Arimidex still saw a benefit, ...
    ... Veridex, LLC, a,Johnson & Johnson company, is pleased ... Lymph Node (BLN) Assay one of the top ten,medical ... of the magazine, available today, TIME,states: "Surgeons now have ... With GeneSearch(TM) BLN Assay, TIME goes on to say, ...
    ... Indiana Plan Combines Personal Responsibility and Public,Dollars, ... announced the approval of a Medicaid waiver that ... innovative health care proposal giving,approximately 120,000 low-income, uninsured ... waiver, the state will be able to begin,accepting ...
    Cached Medicine News:Health News:TFAH Board of Directors Issues Statement on U.S. Health Care Crisis 2Health News:YOU: Staying Young Fourth New York Times Best-Seller for RealAge Test Creator Dr. Michael Roizen! 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 2Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 4Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2
    ... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
    ... is the Bard Kugel Patch, which is constructed ... two layers create a positioning pocket, which is ... position. On the other side is a barrier ... "memory recoil ring," which causes the patch to ...
    ... patch repair is a minimally invasive, tension-free ... small 4-6 cm incision and requires minimal ... through an open, anterior approach that can ... Modified Kugel patch is a self-expanding polypropylene ...
    ... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
    Medicine Products: